Advertisements

Sirdalud 4mg

Quick links to important sections

Sirdalud 4mg

Advertisements
Advertisements

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Advertisements

Overview of Sirdalud 4mg

Property Description
Active ingredient Tizanidine (as hydrochloride)
Form Oral Tablet
Pharmacological class Centrally Acting Skeletal Muscle Relaxant
Common use Symptomatic relief of muscle spasticity
Origin Synthetic

What is Sirdalud 4mg and What is its Purpose?

Sirdalud 4mg is a prescription medicine supplied as an oral tablet that functions as a centrally acting skeletal muscle relaxant. The 4mg strength indicates the amount of active ingredient per dose. The drug is clinically recognized for its efficacy in managing certain types of severe, painful muscle stiffness in patients with chronic neurological conditions.

The main purpose of Sirdalud is to provide relief from spasticity—a condition marked by involuntary muscle tightening and spasms. It is commonly prescribed in a supportive capacity to ease intense muscle rigidity and is available strictly by prescription (Rx), underscoring the need for ongoing medical supervision.


What Kind of Medicine is Sirdalud? (Active Ingredient and Class)

Sirdalud 4mg is a synthetic drug containing tizanidine hydrochloride as its active ingredient. Tizanidine belongs to the pharmacological class known as alpha-2 adrenergic agonists. This drug modulates nerve signals in the spinal cord to reduce muscle hyperactivity.

As a centrally acting agent, tizanidine works by affecting nerve signals in the spinal cord, rather than directly on the muscle fiber itself. The Sirdalud brand is an established, standardized formulation of tizanidine designed for oral administration.


What Does Sirdalud 4mg Help Manage? (Key Conditions)

Sirdalud 4mg is prescribed to help manage the debilitating symptoms of muscle spasticity that arise from underlying neurological disorders, such as multiple sclerosis, spinal cord injury, or sequelae of a stroke. Its role is to specifically address the increased muscle tone and painful spasms that restrict mobility.

The drug's therapeutic goal is to diminish involuntary muscle tightening and associated pain. By achieving this symptomatic relief, Sirdalud can significantly improve a patient's comfort and support the effectiveness of physical rehabilitation.

Regulatory References

  1. NIH Review on Tizanidine
Advertisements

What side effects are possible with Sirdalud 4mg?

Possible Side Effects and Safety Information

The safety profile for Sirdalud 4mg (Tizanidine) is based on official government regulatory classifications of adverse reactions, which define the known risks associated with its use.


Frequency-Classified Adverse Reactions

Adverse effects are categorized by frequency based on clinical trial data and post-marketing surveillance:

  • Very Common (ge 1/10): Somnolence (drowsiness/sedation), dry mouth, fatigue/asthenia.
  • Common (ge 1/100 to <1/10): Dizziness, hypotension (low blood pressure), bradycardia (slow heart rate), nausea, vomiting, and increases in liver transaminases (an indication of liver function change).
  • Rare (ge 1/10,000 to <1/1,000): Hallucination, sleep disorder, insomnia, and hepatitis.
  • Very Rare (<1/10,000): Hepatic failure (severe liver injury).

Clinically Significant Safety Information

Certain adverse reactions are considered serious or require specific safety precautions:

  • Hypotension and Syncope: The medicine can cause significant drops in blood pressure, potentially leading to syncope (fainting) or circulatory collapse. This risk is dose-related.
  • Hepatotoxicity: Severe liver injury, including hepatic failure, has been documented. Monitoring of liver function is officially recommended, especially at higher doses (12 mg or greater).
  • Withdrawal Syndrome: Abrupt discontinuation, particularly after chronic use or high doses, has been associated with a rebound effect, including a rapid and significant increase in blood pressure (rebound hypertension) and tachycardia.
  • Drug Interactions (Contraindications): The medicine is contraindicated (must not be used) with potent inhibitors of the CYP1A2 enzyme, such as fluvoxamine or ciprofloxacin, due to the dangerously increased blood levels of Sirdalud and the associated high risk of severe hypotension and sedation.

Population-Specific Safety Notes

  • Renal Impairment: Caution is required in patients with significantly reduced kidney function (Creatinine Clearance <25 mL/min) as the drug's clearance is reduced, increasing the risk of adverse reactions.
Advertisements

Overdose and Emergency Response

Suspected overdose of Sirdalud (Tizanidine) requires immediate medical attention. The official regulatory profile documents potential for severe central nervous system and cardiovascular depression. Documented clinical manifestations of overdose often include signs of depressed consciousness, such as lethargy, stupor, confusion, and potential progression to coma. Severe symptoms also involve hypotension (low blood pressure) and bradycardia (slow heart rate), as well as respiratory depression. Reported outcomes may include circulatory collapse and have involved fatalities, particularly when Tizanidine was co-ingested with other Central Nervous System (CNS) depressants, including alcohol.

When an overdose is suspected, official guidance mandates that you immediately contact a poison control center or seek emergency services. Management is symptomatic and supportive, as no specific antidote is known. Procedural steps may involve the use of activated charcoal or gastric lavage to remove unabsorbed drug. Following admission, required care involves close observation and continuous monitoring of vital signs and mental status, with electrocardiographic monitoring possibly advisable due to the documented risk of QT(c) prolongation. The overall regulatory classification defines this scenario as potentially life-threatening.

Advertisements

Therapeutic Uses of Sirdalud 4mg

Quick Facts

  • Therapeutic Domain: May help manage increased muscle tone (spasticity).
  • Associated Conditions: Used in the management of spasticity linked to conditions like multiple sclerosis (MS) and spinal cord injury.

Sirdalud (tizanidine) is an approved medication indicated for the relief of muscle spasticity in adults. This therapeutic agent is intended for the short-term management of increased muscle tone and involuntary muscle tightening that can interfere with daily activities.

The medication is used to provide relief from spasticity resulting from neurological conditions, which may include multiple sclerosis, spinal cord injury, or traumatic brain injury. By addressing muscle tightness and cramping, tizanidine may support improved comfort, mobility, and patient function.

The use of tizanidine should be reserved for periods when the relief of spasticity symptoms is considered most important for functional activities, due to its relatively short duration of therapeutic effect. This medication does not provide a cure for the underlying conditions causing the spasticity.

Advertisements

Eligibility and Restrictions for Use

Who can and cannot use Sirdalud 4mg?

The eligibility for Sirdalud 4mg (tizanidine) is strictly defined by official regulatory documentation, focusing on contraindications, age, and pre-existing medical conditions.

Populations Not Eligible (Contraindications)

  • Hypersensitivity: Patients with a known allergy to tizanidine or any component of the tablet formulation must not use this medicine.
  • Strong CYP1A2 Inhibitors: Concomitant use with strong inhibitors of the CYP1A2 enzyme, such as ciprofloxacin or fluvoxamine, is prohibited.
  • Severe Hepatic Impairment: The medication is contraindicated in patients with severely impaired liver function.

Conditional and Restricted Use

  • Age: The medicine is approved only for adults. Safety and effectiveness have not been established in pediatric patients (under 18 years).
  • Organ Function: Caution and close monitoring are required for patients with renal impairment or mild to moderate hepatic impairment. Use is restricted in severe renal impairment.
  • Pregnancy/Lactation: Use during pregnancy is generally restricted due to insufficient human data. The medication is generally not recommended while breastfeeding.
  • Older Adults: Use is permitted but requires caution due to potential for increased sensitivity to effects.
Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Regulatory documentation defines specific interactions with tizanidine that are classified based on the potential for altered plasma exposure or additive pharmacodynamic effects.

Contraindicated Combinations

Co-administration with potent CYP1A2 inhibitors is formally contraindicated due to the high risk of severely increased tizanidine exposure (plasma concentrations). These interactions result from the inhibition of Cytochrome P450 1A2 (CYP1A2), the primary enzyme responsible for tizanidine clearance. Specific medicines in this prohibited category include fluvoxamine and ciprofloxacin, which can increase tizanidine exposure by up to 33-fold and 10-fold, respectively, leading to severe adverse outcomes.

Significant Pharmacodynamic and Exposure Interactions

Other agents that inhibit CYP1A2, such as oral contraceptives or moderate inhibitors like zileuton and cimetidine, can reduce tizanidine clearance, which may necessitate caution. Co-administration with alcohol and other CNS depressants (including opioids and benzodiazepines) is not recommended due to additive sedative effects. Similarly, combining tizanidine with antihypertensive drugs carries the risk of additive hypotensive effects, potentially causing clinically significant low blood pressure.

Population and Food Context

Use in patients with severe hepatic impairment is contraindicated due to significantly reduced drug clearance, which exacerbates the risk of increased exposure and interaction severity. The label notes that consistent administration relative to food is advised to minimize variability in tizanidine plasma concentrations.

Advertisements

Mechanism of Action

How Sirdalud 4mg Works: Mechanism of Action

Sirdalud (Tizanidine) functions as an agonist at central alpha2-adrenergic receptors, primarily those located on inhibitory interneurons within the spinal cord. This targeted molecular interaction represents the initial step in its mechanism. Receptor activation leads to a suppression of excitatory signaling from presynaptic terminals by decreasing the release of excitatory amino acids, such as glutamate.

This neurochemical event results in the inhibition of polysynaptic reflex pathways—the complex nerve circuits in the spinal cord that exhibit heightened activity. By dampening this excitatory drive, the drug lowers the overall excitability of spinal motor neurons. This physiological adjustment limits the capacity of motor neurons to sustain high-frequency firing, which translates to a decrease in the activity level of the motor neuron pool and a modification of the resultant muscle tension.

Advertisements

Dosage and Administration Information

Oral Administration and Dosing Protocol

Sirdalud (tizanidine) is approved solely for the oral route of administration as a tablet. The official usage protocol mandates a process of individualized dose titration to establish the lowest effective amount. Treatment is initiated with a low starting dose, typically 2 mg, taken in divided doses. The dose may be repeated up to three times daily, with doses spaced by approximately 6 to 8 hours. The maximum total daily dosage must not exceed 36 mg.


Titration, Consistency, and Special Populations

Dosage increases are made gradually in small increments of 2 mg to 4 mg per dose. A crucial procedural step requires a waiting period of 1 to 4 days between adjustments to properly evaluate the clinical response before increasing the dose. The 4 mg tablet is scored, which facilitates division when smaller, incremental doses are required during the titration phase.

Administration must maintain consistency with food. The patient should adhere to a fixed routine of always taking the dose with food or always without food, as changing this pattern significantly alters the drug's absorption. For patients with severe renal impairment (creatinine clearance < 25 mL/min), the protocol requires a reduced starting dose, such as 2 mg once daily, and subsequent increases must prioritize the size of the individual dose over the frequency of administration. When concluding therapy, the drug must be gradually tapered by 2 mg to 4 mg per day.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sirdalud 4mg


Evidence for Spasticity in Multiple Sclerosis and Spinal Cord Injury

Research was conducted on spasticity, a condition marked by functional limitations. The design primarily involved short-term randomized controlled trials (RCTs) exploring how symptoms change over time. Research monitored outcomes related to physical discomfort, as well as measures of muscle tone and the frequency of muscle spasms.

Research reports changes measured during the study period. Studies explored how symptoms evolved in the observed populations, and data contained patterns of change in muscle tone compared to control groups over short time intervals. Findings describe patterns observed in the studies that also involved patient-reported outcomes describing perceived discomfort and evaluations of symptom status.

Evidence for Spasticity Following a Stroke

Research examined tizanidine for spasticity following a stroke, which is a condition marked by functional limitations. The evidence base included dose-titration studies, some of which were conducted in settings where the substance being administered was known. Research monitored changes in muscle stiffness and patient-reported outcomes describing perceived discomfort.

Findings indicate patterns related to measured changes in muscle tone in individuals with chronic symptoms. Research describes that during the observed time intervals, research also explored outcomes related to physical discomfort. One study reported no significant change in certain objective measures of functional ability (such as performance in activities of daily living); measured muscle tone changes were also reported in that study.


The Study Landscape: Key Limitations and Remaining Uncertainty

Key research limitation frames include the fact that sample sizes were modest in some pivotal trials. There is a consistent gap related to outcomes reflecting daily functioning: while objective measurements of muscle tone were studied, the influence on an individual's actual ability to perform daily tasks is an area where evidence is limited.

Follow-up durations were often limited. The persistence of the patterns observed in the studies is an area where data are still emerging, and long-term effects are not fully established. Furthermore, data for certain groups remain insufficient, as results apply mainly to the adult populations studied in the main regulatory trials.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Sirdalud 4mg (FAQ)


Q: How quickly should I expect to feel the effects of Sirdalud 4mg?

A: According to official regulatory documents, the maximum effects of Sirdalud (tizanidine) are typically reached about one to two hours after a dose is taken. This timing reflects when the concentration of the drug in the bloodstream is highest. The onset of muscle relaxing effects may vary among patients.

Q: How long do the effects of Sirdalud 4mg typically last?

A: Studies indicate that the effects of the medication generally start to diminish between three and six hours after administration. Due to this duration, the drug may be prescribed for administration multiple times a day. The precise duration of effect can vary between individuals.

Q: Can Sirdalud 4mg be taken with common over-the-counter pain relievers?

A: Official drug information does not specifically list common non-sedating over-the-counter pain relievers (like acetaminophen or ibuprofen) as having known significant interactions with Sirdalud. However, since Sirdalud can cause sedation, patients are generally advised to discuss all combinations with a healthcare provider.

Q: What's the difference between Sirdalud 4mg and Tizanidine?

A: Sirdalud is a brand name for the active chemical ingredient, which is tizanidine. They refer to the same drug. The 4 mg indicates the specific amount of tizanidine hydrochloride present in each tablet formulation.

Q: Does Sirdalud 4mg help with nerve pain or only muscle spasms?

A: Sirdalud is officially indicated and approved for managing muscle spasticity, which involves involuntary muscle tightening and spasms. Its use is not specifically indicated or approved for nerve pain (neuropathic pain).

Q: Are there any common foods or drinks that interact negatively with Sirdalud 4mg?

A: Official information advises against co-administration with alcohol, as it can significantly increase the sedative effects of the medication. Consistency is also important: a patient should consistently take the drug either with food or without it, because changing this pattern can alter how the drug is absorbed.

Q: Can older people generally use Sirdalud 4mg safely?

A: The medication is approved for adult use, but caution is specifically advised for older adults. Due to potential increased sensitivity, older patients may be more susceptible to certain side effects, such as low blood pressure.

Q: Does Sirdalud 4mg have the potential for withdrawal symptoms if stopped suddenly?

A: Yes, regulatory warnings advise that abrupt discontinuation, particularly following chronic or high-dose use, is associated with a withdrawal syndrome. This can include rebound hypertension (a rapid, severe blood pressure increase). For this reason, a gradual dose reduction is part of the prescribing recommendations.

Q: How long can someone typically be on Sirdalud 4mg?

A: Clinical experience with long-term use, especially at higher doses, is limited in the official studies. The duration of therapy is determined on an individual basis by the prescribing healthcare professional, taking into account the patient's needs and the available evidence.

Q: What are the precautions for operating machinery while taking Sirdalud 4mg?

A: Sirdalud can cause side effects like sedation, drowsiness, and dizziness. Official safety information recommends caution when driving a car or operating heavy machinery until a patient understands how the medication affects their coordination and mental alertness.

Q: Can Sirdalud 4mg be taken with certain antidepressants?

A: Official information indicates that co-use with the antidepressant fluvoxamine is contraindicated (prohibited). Caution is also necessary with other antidepressants that inhibit the CYP1A2 enzyme or cause sedation, as this may increase the risk of side effects.

Q: Is Sirdalud 4mg similar to cyclobenzaprine?

A: Both Sirdalud (tizanidine) and cyclobenzaprine are in the class of skeletal muscle relaxants. However, Sirdalud is typically used for spasticity related to chronic neurological conditions, while cyclobenzaprine is more commonly prescribed for short-term relief of acute muscle spasms.

Q: Is Sirdalud 4mg suitable for long-term use?

A: Official research data on the long-term effects of Sirdalud, especially at high doses, is limited. Use over an extended period should be assessed by the prescribing healthcare professional who will weigh the drug's benefits against the limited available long-term safety data.

Q: Are there specific symptoms that Sirdalud 4mg is best at treating?

A: The drug is officially indicated for the symptomatic treatment of increased muscle tone and spasms associated with spasticity. The regulatory label describes its role in easing these symptoms to improve physical function, but it does not specify a superior benefit for one specific spasticity symptom over others.

Q: Does Sirdalud 4mg interact with birth control pills?

A: Yes, official drug interaction data indicates that oral contraceptives containing estrogen may increase the blood level of Sirdalud. This could potentially increase the risk of side effects, such as drowsiness and low blood pressure. Dosage adjustments may be necessary.

Q: Is Sirdalud 4mg considered a controlled substance?

A: No, Sirdalud (tizanidine) is not typically classified as a controlled substance by regulatory bodies like the U.S. Drug Enforcement Administration (DEA).

Q: Can Sirdalud 4mg affect heart rhythm?

A: Official safety information notes that Sirdalud can cause bradycardia, which is an abnormally slow heart rate. It is also associated with a drop in blood pressure (hypotension).

Q: Can Sirdalud 4mg affect sleep patterns?

A: Sirdalud is associated with somnolence (drowsiness) as a very common side effect. Less commonly, regulatory documents also list sleep disorders and insomnia (difficulty falling asleep) as reported side effects.

Q: Why is Sirdalud 4mg sometimes prescribed for conditions other than back pain?

A: The drug's official indication is for the symptomatic treatment of spasticity resulting from severe neurological conditions such as multiple sclerosis, spinal cord injury, or stroke. These are the conditions for which the drug is approved and for which efficacy has been established.

Q: Can Sirdalud 4mg be crushed or chewed?

A: The drug is supplied as an oral tablet, and while the 4 mg tablet is scored to allow for division, the official label does not provide instructions for crushing or chewing the tablet. Any changes to administration, such as crushing, should be directed by a clinician.

Q: Is the drowsiness from Sirdalud 4mg likely to lessen over time?

A: Data from clinical studies indicate that the frequency of sedation peaked shortly after starting the titration process and then generally remained stable for the duration of the studies. This suggests the drowsiness may not lessen significantly over time for all individuals.

Q: Can athletes use Sirdalud 4mg for muscle injuries?

A: The official use of Sirdalud is restricted to treating spasticity, which is muscle stiffness resulting from chronic neurological disorders. It is not indicated or approved for treating acute, non-neurological muscle injuries or spasms.

Q: Is Sirdalud 4mg effective for chronic muscle pain?

A: Sirdalud is officially indicated for spasticity, a specific form of muscle stiffness and spasm related to neurological conditions. Its approved use is not for treating general chronic muscle pain that is not related to spasticity.

Q: What kind of drug-to-drug interactions are considered high-risk with Sirdalud 4mg?

A: High-risk, contraindicated interactions include co-use with potent inhibitors of the CYP1A2 enzyme, such as the drugs ciprofloxacin and fluvoxamine. Combining Sirdalud with other central nervous system depressants (like opioids) is also considered high-risk due to the danger of excessive sedation.

Q: Is Sirdalud 4mg commonly prescribed in physical therapy settings?

A: The drug is used to relieve spasticity and muscle stiffness. By reducing these symptoms, official sources suggest Sirdalud can help support the effectiveness of physical rehabilitation. The location where the prescription is administered is a medical decision.

Q: What is the evidence regarding Sirdalud 4mg's effectiveness versus placebo?

A: Clinical trials reviewed by regulatory bodies have established that patients receiving Sirdalud showed measurable changes in muscle tone compared to patients who received a placebo. This evidence supports its use for the reduction of spasticity symptoms.

Q: Is Sirdalud 4mg safe for breastfeeding mothers?

A: Official information states that it is not known whether tizanidine is excreted in human milk. Due to the potential for the drug to cause adverse reactions in the infant, regulatory information suggests that a decision must be made regarding discontinuing the drug or discontinuing nursing.

Q: Why do some people experience hallucinations or vivid dreams on Sirdalud 4mg?

A: Regulatory warnings note that Sirdalud use has been associated with hallucinations and psychotic-like symptoms. While it is listed as a known adverse reaction, the detailed neurochemical reason for this specific effect is not fully described in the patient information.

Q: Are there specific laboratory tests needed before starting Sirdalud 4mg?

A: Official safety information recommends monitoring of liver enzyme levels at baseline (before starting treatment). Liver enzyme monitoring is typically recommended at baseline and after the dose is stabilized.

Q: How does Sirdalud 4mg affect reaction time?

A: Because Sirdalud can cause sedation, dizziness, and somnolence, these effects may impair a person's reaction time. Patients are advised to exercise caution during activities that require high levels of mental alertness.

Q: Is it common to have stomach upset from Sirdalud 4mg?

A: Regulatory adverse reaction data classify both nausea and vomiting as common side effects of the medication. Other forms of stomach upset are also possible and should be reported to a healthcare provider.

Q: Can Sirdalud 4mg be taken on an empty stomach?

A: The tablet may be taken either with food or without food. However, it is important that consistency is maintained in the dosing regimen, as switching between taking it with food and taking it without food can significantly change how the drug is absorbed.

Q: How is the 4mg strength different from other available Sirdalud strengths?

A: The 4 mg strength simply indicates the specific quantity of the active ingredient (tizanidine) contained in each tablet. The choice of which strength to use is part of the individualized dose titration process determined by the healthcare provider.

Advertisements

How should Sirdalud 4mg be stored and disposed of?

Tizanidine (Sirdalud) 4 mg tablets must be stored according to official regulatory specifications to maintain product integrity and ensure safety.

Scope Item Official Regulatory Requirement
Labeled storage temperature requirements: Store at 25 C (77 F); Excursions permitted 15 C to 30 C (59 F to 86 F) (Controlled Room Temperature).
Light/moisture protection requirements: Store away from excess heat, moisture, and direct light.
Packaging-related storage rules: Keep in the original container, tightly closed, and ensure it has a child resistant closure.
Child-protection storage requirements: Keep out of the sight and reach of children and pets.

Official Disposal Statements

  • Unused or outdated medication must not be kept.
  • Disposal must be conducted according to local environmental requirements and regulations.
  • Patients should consult a healthcare professional for guidance on disposing of any unused medicine.

These requirements define the necessary storage environment as Controlled Room Temperature, protected from environmental factors. The product must be securely kept in its original, closed container with a child-resistant closure, and proper disposal according to local rules is mandatory for unneeded or expired tablets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Sirdalud 4mg found in:

A-Z Index: